▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Huons reports positive clinical results for dry eye-fighting drops

  • PUBLISHED :December 19, 2017 - 15:23
  • UPDATED :December 19, 2017 - 16:48
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Huons, a subsidiary of Huons Global, on Dec. 19 announced positive results for its nanocomposite eye drops used for treating dry eye syndrome HU007 in its phase 2 clinical trials.

The company presented the clinical study data at the European Ophthalmology Congress & Ocular Pharmacology Conference 2017, in Rome, Italy, on Dec. 5. 

“The drug candidate was found to offer clinically meaningful benefits for the tear film protection and has anti-inflammatory effects,” said Joo Chun-ki, professor at the Catholic University of Korea Gangnam St. Mary Hospital and principal investigator for the clinical program.

Some 105 adult patients with dry eye syndrome participated in the multicenter, placebo controlled, randomized, double-blind study to evaluate the efficacy and safety of the investigational drug, according to registry disclosure site clinicaltrials.gov.

By using nanoparticles, HU007 ensures that more of the active ingredient reaches the eyes. The nanoparticles of less than 20 nm diameter also enhance patients’ convenience as they are not required to shake the eye drop bottle before using, the company said.

Huons said it plans to receive marketing approval from Korea’s Ministry of Food and Drug Safety in 2019. The regulator has cleared the company’s Investigational New Drug application to conduct phase 3 studies of HU007 in October.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS